logo-loader
viewFutura Medical PLC

Futura Medical's Ken James updates on EU and US regulatory progress for MED3000

Futura Medical PLC's (LON:FUM) Ken James speaks to Proactive London's Andrew Scott after announcing it's submitted the product dossier for its treatment of erectile dysfunction known as MED3000 for marketing approval in Europe. In the US, James says that after a second pre-submission meeting with the US Food and Drug Administration (FDA), a pathway to US marketing approval for MED3000 has been established.

Quick facts: Futura Medical PLC

Price: 15.155 GBX

AIM:FUM
Market: AIM
Market Cap: £37.22 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Futura Medical PLC named herein, including the promotion by the Company of Futura Medical PLC in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Futura Medical gets set to begin formal approval steps for erectile...

Futura Medical PLC’s (LON:FUR) James Barder talks to Proactive London’s Katie Pilbeam about the highlights in their half-year report which includes the latest on MED3000 - a topical treatment for Erectile Dysfunction. Proceedings have begun for formal approval of the drug to be approved as a...

5 days, 22 hours ago

2 min read